Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CHRNA7 | P36544 | 1/20 | 0.45 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.40 |
| ▸ | CHRM2 | P08172 | 4/20 | 0.39 |
| ▸ | CYP2D6 | P10635 | 2/20 | 0.39 |
| ▸ | CHRM1 | P11229 | 2/20 | 0.39 |
| ▸ | MEN1 | O00255 | 1/20 | 0.39 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.39 |
| ▸ | CHRM3 | P20309 | 2/20 | 0.37 |
| ▸ | EGFR | P00533 | 1/20 | 0.37 |
| ▸ | POLB | P06746 | 1/20 | 0.37 |
| ▸ | HTR1A | P08908 | 1/20 | 0.37 |
| ▸ | ADRA2A | P08913 | 1/20 | 0.37 |
| ▸ | ADORA3 | P0DMS8 | 1/20 | 0.37 |
| ▸ | MAPT | P10636 | 1/20 | 0.37 |
| ▸ | DRD2 | P14416 | 1/20 | 0.37 |
| ▸ | ADRA2B | P18089 | 1/20 | 0.37 |
| ▸ | ADRA2C | P18825 | 1/20 | 0.37 |
| ▸ | DRD1 | P21728 | 1/20 | 0.37 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.37 |
| ▸ | HTR2A | P28223 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL660508 | 1.00 | CHRNA7 (0.45) | CHRNA7ALDH1A1CHRM2CYP2D6CHRM1 | |
| SCHEMBL9698974 | 0.90 | CHRNA7 (0.39) | CHRNA7ALDH1A1CHRM2CYP2D6CHRM1 | |
| SCHEMBL21063738 | 0.82 | CHRNA7 (0.41) | CHRNA7CHRM2CYP2D6CHRM1MEN1 | |
| SCHEMBL4280104 | 0.82 | CHRNA7 (0.41) | CHRNA7CHRM2CYP2D6CHRM1MEN1 | |
| SCHEMBL21063808 | 0.82 | CHRNA7 (0.41) | CHRNA7CHRM2CYP2D6CHRM1MEN1 | |
| Hydrochloric Acid SCHEMBL23406281 | 0.80 | SLC6A12 (0.42) | CHRNA7CHRM2CYP2D6CHRM1MEN1 | |
| SCHEMBL6650217 | 0.80 | CHRNA7 (0.40) | CHRNA7ALDH1A1CHRM2CYP2D6CHRM1 | |
| SCHEMBL29271818 | 0.80 | CHRNA7 (0.40) | CHRNA7CHRM2CYP2D6CHRM1MEN1 | |
| SCHEMBL12506844 | 0.80 | CHRM2 (0.47) | CHRNA7CHRM2CYP2D6CHRM1MEN1 | |
| SCHEMBL25607288 | 0.80 | CHRM2 (0.47) | CHRNA7CHRM2CYP2D6CHRM1MEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250129091-A1 | THIENOPYRROLOTRIAZINE COMPOUNDS, THEIR PREPARATION AND THEIR THERAPEUTIC USE | SANOFI (FR) | 2025-04-24 | — | — | US | disclosed |
| EP-3724183-A1 | SUBSTITUTED INDOLE ETHER COMPOUNDS | Bristol-Myers Squibb Company (US) | 2020-10-21 | — | — | EP | disclosed |
| WO-2019118799-A1 | SUBSTITUTED INDOLE ETHER COMPOUNDS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2019-06-20 | — | — | WO | disclosed |
| EP-1404675-A1 | DPP-IV-INHIBITING PURINE DERIVATIVES FOR THE TREATMENT OF DIABETES | NOVO NORDISK A/S (DK) | 2004-04-07 | — | — | EP | disclosed |
| WO-2003004496-A1 | DPP-IV-INHIBITING PURINE DERIVATIVES FOR THE TREATMENT OF DIABETES | NOVO NORDISK A/S (DK) | 2003-01-16 | — | — | WO | disclosed |
| US-5091397-A | Cognition activators | BEECHAM GROUP P.L.C. (GB) | 1992-02-25 | — | — | US | disclosed |
| EP-0363085-A2 | Novel compounds | BEECHAM GROUP PLC (GB) | 1990-04-11 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250129091-A1 | THIENOPYRROLOTRIAZINE COMPOUNDS, THEIR PREPARATION AND THEIR THERAPEUTIC USE | TPMT, TYMP, TBXA2R | CHRNA7 586/4885ALDH1A1 1207/4885CHRM2 1276/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.